The Women in Cancer Immunotherapy Network (WIN) Leadership Institute returns this summer and will grow to two programs, in Seattle (July 13–14) and Chicago (Aug. 3–4).The one-and-a-half-day programs celebrate and empower emerging women leaders in the cancer immunotherapy field.
This year, SITC is offering young investigators $600,000 in funding to advance their cancer immunotherapy research through six fellowships and a new, unique award.
Interested applicants may apply for more than one opportunity. Applications are due by Friday, Feb. 28, at 5 p.m. PST.
Attend the SITC Interrogating the Tumor-Specific Surfaceome for Immune Targeting Workshop on April 23–24, 2020, in San Diego.
This workshop will provide an intimate opportunity for attendees to discuss their work with experts in the field. Abstracts are due by Friday, Feb. 28, at 5 p.m. PST. Encore presentations welcome!
Join Jennifer Guerriero, PhD, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
Read the manuscript, Defining Current Gaps in Quality Measures for Cancer Immunotherapy: Consensus Report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit, as published in the Journal for ImmunoTherapy of Cancer.
Now Available: SITC Consensus Statement on Immunotherapy for the Treatment of Advanced Renal Cell Carcinoma
New Online Patient Course Available: Understanding Cancer Immunotherapy Access SITC’s dedicated resource for patients and caregivers to learn about cancer immunotherapy
2020 Multidisciplinary Head and Neck Cancers SymposiumAttend the symposium Feb. 27–29, 2020, in Scottsdale, Ariz. This practical and interactive meeting is for the entire head and neck cancer care community.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
On November 26, 2018, the Food and Drug Administration granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene ...
Please send any information of this drug Thank in advance Sent from my iPhone
Join more than 50 stellar speakers at AI and Big Data in Cancer (March 29-31, 2020, Boston) to explore a pragmatic approach to effectively translate technology, data and analytic innovations into clinical practices and patient benefit.
An exceptional ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com